Donepezil appears not to be effective in preventing the development of Alzheimer's disease during 3 years' treatment in patients with mild cognitive impairment (MCI, MMSE > 23) and its use is associated with a significant incidence of side effects. Donepezil appears to be associated with a modest and clinically questionable benefit on a 13-item the ADAS-Cog scale but not on other measures of cognitive functionDonepezil for Mild Cognitive Impairment.